TY - JOUR
T1 - State-of-The-Art management of dysplastic Barrett's esophagus
AU - Vantanasiri, Kornpong
AU - Iyer, Prasad G.
N1 - Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University.
PY - 2022
Y1 - 2022
N2 - Endoscopic eradication therapy (EET) has become a standard of care for treatment of dysplastic Barrett's esophagus (BE) and early Barrett's neoplasia. EET mainly consists of removal of any visible lesions via endoscopic resection and eradication of all remaining Barrett's mucosa using endoscopic ablation. Endoscopic mucosal resection and endoscopic submucosal dissection are the two available resection techniques. After complete resection of all visible lesions, it is crucial to perform endoscopic ablation to ensure complete eradication of the remaining Barrett's segment. Endoscopic ablation can be done either with thermal techniques, including radiofrequency ablation and argon plasma coagulation, or cryotherapy techniques. The primary end point of EET is achieving complete remission of intestinal metaplasia (CRIM) to decrease the risk of dysplastic recurrence after successful EET. After CRIM is achieved, a standardized endoscopic surveillance protocol needs to be implemented for early detection of BE recurrence.
AB - Endoscopic eradication therapy (EET) has become a standard of care for treatment of dysplastic Barrett's esophagus (BE) and early Barrett's neoplasia. EET mainly consists of removal of any visible lesions via endoscopic resection and eradication of all remaining Barrett's mucosa using endoscopic ablation. Endoscopic mucosal resection and endoscopic submucosal dissection are the two available resection techniques. After complete resection of all visible lesions, it is crucial to perform endoscopic ablation to ensure complete eradication of the remaining Barrett's segment. Endoscopic ablation can be done either with thermal techniques, including radiofrequency ablation and argon plasma coagulation, or cryotherapy techniques. The primary end point of EET is achieving complete remission of intestinal metaplasia (CRIM) to decrease the risk of dysplastic recurrence after successful EET. After CRIM is achieved, a standardized endoscopic surveillance protocol needs to be implemented for early detection of BE recurrence.
KW - Barrett's esophagus
KW - endoscopic eradication therapy
KW - endoscopic mucosal resection
KW - endoscopic submucosal dissection
KW - esophageal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85144983519&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144983519&partnerID=8YFLogxK
U2 - 10.1093/gastro/goac068
DO - 10.1093/gastro/goac068
M3 - Review article
AN - SCOPUS:85144983519
SN - 2052-0034
VL - 10
JO - Gastroenterology Report
JF - Gastroenterology Report
M1 - goac068
ER -